Details of the Drug Combination

General Information of Drug Combination (ID: DCTNGZW)

Drug Combination Name

MK-2206 cycloheximide

Indication

Disease Entry	Status	REF
Ewing sarcoma	Investigative	[1]

Component Drugs

MK-2206 DMT1OZ6

cycloheximide DMGDA3C

Small molecular drug

2D MOL

3D MOL

3D MOL is unavailable

High-throughput Screening Result

Testing Cell Line: TC-71

Zero Interaction Potency (ZIP) Score: 14.686

Bliss Independence Score: 22.848

Loewe Additivity Score: 1.716

LHighest Single Agent (HSA) Score: 3.607

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of MK-2206

Disease Entry	ICD 11	Status	REF
Rectal adenocarcinoma	2B92	Phase 2	[2]
Nasopharyngeal carcinoma	2B6B	Investigative	[3]

MK-2206 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
RAC-gamma serine/threonine-protein kinase (AKT3)	TTAZ05C	AKT3_HUMAN	Modulator	[6]
E2 ubiquitin-conjugating enzyme T (UBE2T)	TT0A1R8	UBE2T_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

MK-2206 Interacts with 20 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Expression	[7]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Decreases Secretion	[5]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Increases Expression	[7]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Secretion	[5]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Decreases Expression	[5]
Tissue factor (F3)	OT3MSU3B	TF_HUMAN	Increases Expression	[8]
Vascular endothelial growth factor receptor 1 (FLT1)	OTT0OGYS	VGFR1_HUMAN	Decreases Expression	[5]
Interleukin-10 (IL10)	OTIRFRXC	IL10_HUMAN	Increases Secretion	[5]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[5]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Affects Response To Substance	[9]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[10]
T-lymphocyte activation antigen CD80 (CD80)	OTJBLUQE	CD80_HUMAN	Decreases Expression	[5]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Decreases Expression	[5]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[10]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Decreases Expression	[5]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Decreases Expression	[11]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Decreases Phosphorylation	[10]
Interferon regulatory factor 8 (IRF8)	OT8YSNI4	IRF8_HUMAN	Decreases Expression	[5]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1)	OTHBQVD5	4EBP1_HUMAN	Decreases Phosphorylation	[10]
Proline-rich AKT1 substrate 1 (AKT1S1)	OT4JHN4Y	AKTS1_HUMAN	Decreases Phosphorylation	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DOT(s)

Indication(s) of cycloheximide

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[4]

cycloheximide Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[20]
------------------------------------------------------------------------------------

cycloheximide Interacts with 120 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Increases Expression	[21]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[13]
ATP-binding cassette sub-family C member 5 (ABCC5)	OT34G4US	MRP5_HUMAN	Decreases Expression	[13]
Transforming acidic coiled-coil-containing protein 1 (TACC1)	OTGX20TE	TACC1_HUMAN	Increases Expression	[13]
Trefoil factor 1 (TFF1)	OTCYQH4F	TFF1_HUMAN	Increases Expression	[13]
Receptor tyrosine-protein kinase erbB-2 (ERBB2)	OTOAUNCK	ERBB2_HUMAN	Decreases Expression	[13]
Amphiregulin (AREG)	OTJFOR67	AREG_HUMAN	Increases Expression	[13]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[13]
Insulin-like growth factor-binding protein 4 (IGFBP4)	OT2HZRBD	IBP4_HUMAN	Increases Expression	[13]
Insulin receptor substrate 1 (IRS1)	OTNO82CU	IRS1_HUMAN	Decreases Expression	[13]
CCN family member 3 (CCN3)	OTOW5YL4	CCN3_HUMAN	Increases Expression	[13]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Increases Expression	[22]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Decreases Expression	[22]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Decreases Activity	[23]
Dynamin-1-like protein (DNM1L)	OTXK1Q1G	DNM1L_HUMAN	Increases Expression	[24]
Apoptotic protease-activating factor 1 (APAF1)	OTJWIVY0	APAF_HUMAN	Decreases Expression	[24]
Glycosylphosphatidylinositol anchor attachment 1 protein (GPAA1)	OTWVRR35	GPAA1_HUMAN	Increases Expression	[24]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Increases Expression	[24]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Increases Expression	[24]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1)	OTM0GDTP	IF2A_HUMAN	Increases Expression	[24]
Protein kinase C beta type (PRKCB)	OTYQ0656	KPCB_HUMAN	Decreases Expression	[24]
Glia-derived nexin (SERPINE2)	OTYF5340	GDN_HUMAN	Increases Expression	[24]
ETS domain-containing protein Elk-1 (ELK1)	OTH9MXD6	ELK1_HUMAN	Increases Expression	[24]
Pleiotrophin (PTN)	OTYC7M2A	PTN_HUMAN	Increases Expression	[24]
CCN family member 2 (CCN2)	OTC39NSU	CCN2_HUMAN	Increases Expression	[24]
Kappa-type opioid receptor (OPRK1)	OTXCZF4L	OPRK_HUMAN	Increases Expression	[24]
Collagenase 3 (MMP13)	OTY8BZIE	MMP13_HUMAN	Increases Expression	[24]
Heterogeneous nuclear ribonucleoprotein H2 (HNRNPH2)	OTMGP4J7	HNRH2_HUMAN	Increases Expression	[24]
Single-stranded DNA-binding protein, mitochondrial (SSBP1)	OTH2PZWH	SSBP_HUMAN	Increases Expression	[24]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[24]
Mitogen-activated protein kinase 7 (MAPK7)	OTF7H7L7	MK07_HUMAN	Increases Expression	[24]
Pappalysin-1 (PAPPA)	OTTTG9PG	PAPP1_HUMAN	Increases Expression	[24]
SERTA domain-containing protein 2 (SERTAD2)	OTYIG6TP	SRTD2_HUMAN	Increases Expression	[24]
Next to BRCA1 gene 1 protein (NBR1)	OTVRL7J9	NBR1_HUMAN	Increases Expression	[24]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Increases Expression	[24]
5'-3' exonuclease PLD3 (PLD3)	OTL07SP2	PLD3_HUMAN	Increases Expression	[24]
Synaptopodin (SYNPO)	OTICDJAB	SYNPO_HUMAN	Increases Expression	[24]
Transmembrane protein 263 (TMEM263)	OTO1RSTS	TM263_HUMAN	Increases Expression	[24]
Alpha-N-acetylneuraminide alpha-2,8-sialyltransferase (ST8SIA1)	OTGND2YZ	SIA8A_HUMAN	Increases Expression	[24]
Sororin (CDCA5)	OTZLCQ5U	CDCA5_HUMAN	Increases Expression	[24]
Retinoic acid receptor responder protein 2 (RARRES2)	OT1BJE8K	RARR2_HUMAN	Increases Expression	[24]
Solute carrier family 22 member 4 (SLC22A4)	OT4LOVI9	S22A4_HUMAN	Increases Expression	[24]
CDC42 small effector protein 2 (CDC42SE2)	OT8SG9I1	C42S2_HUMAN	Increases Expression	[24]
Myotubularin-related protein 7 (MTMR7)	OT47NVYM	MTMR7_HUMAN	Increases Expression	[24]
Small ribosomal subunit protein uS7m (MRPS7)	OT57AX7G	RT07_HUMAN	Decreases Expression	[24]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Decreases Expression	[25]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Decreases Expression	[26]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Increases Expression	[27]
NADPH--cytochrome P450 reductase (POR)	OTVIDOCH	NCPR_HUMAN	Decreases Expression	[28]
Tumor protein p53-inducible protein 11 (TP53I11)	OTFPDYZU	P5I11_HUMAN	Decreases Expression	[29]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[30]
Transcription regulator protein BACH1 (BACH1)	OTY8004K	BACH1_HUMAN	Decreases Expression	[31]
Proepiregulin (EREG)	OTRM4NQY	EREG_HUMAN	Increases Expression	[32]
CASP8 and FADD-like apoptosis regulator (CFLAR)	OTX14BAS	CFLAR_HUMAN	Decreases Expression	[33]
Autophagy-related protein 13 (ATG13)	OTYMHNEJ	ATG13_HUMAN	Decreases Expression	[16]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A)	OTYG179K	PR15A_HUMAN	Decreases Expression	[34]
Mitochondrial uncoupling protein 4 (SLC25A27)	OTSBOPGD	UCP4_HUMAN	Increases Expression	[35]
Epidermal growth factor receptor (EGFR)	OTAPLO1S	EGFR_HUMAN	Increases Expression	[32]
Protein c-Fos (FOS)	OTJBUVWS	FOS_HUMAN	Increases Expression	[36]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Decreases Expression	[37]
Protransforming growth factor alpha (TGFA)	OTPD1LL9	TGFA_HUMAN	Increases Expression	[32]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Decreases Activity	[38]
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Decreases Expression	[39]
Superoxide dismutase , mitochondrial (SOD2)	OTIWXGZ9	SODM_HUMAN	Increases Expression	[40]
Cytochrome P450 2E1 (CYP2E1)	OTHQ17JG	CP2E1_HUMAN	Increases Degradation	[41]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Increases Expression	[42]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[43]
Transcription factor AP-2-alpha (TFAP2A)	OTMYT3NK	AP2A_HUMAN	Decreases Stability	[44]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Increases Expression	[45]
Rho-related GTP-binding protein RhoC (RHOC)	OTOLE1FT	RHOC_HUMAN	Decreases Expression	[46]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[47]
Intestinal-type alkaline phosphatase (ALPI)	OTTQ468O	PPBI_HUMAN	Decreases Activity	[48]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Increases Expression	[42]
E3 SUMO-protein ligase EGR2 (EGR2)	OTAVQ78J	EGR2_HUMAN	Increases Expression	[49]
Steroid hormone receptor ERR1 (ESRRA)	OTTDTUSP	ERR1_HUMAN	Decreases Expression	[50]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Increases Expression	[42]
C-C motif chemokine 5 (CCL5)	OTSCA5CK	CCL5_HUMAN	Increases Expression	[42]
Nuclear factor NF-kappa-B p105 subunit (NFKB1)	OTNRRD8I	NFKB1_HUMAN	Increases Expression	[42]
Receptor tyrosine-protein kinase erbB-3 (ERBB3)	OTRSST0A	ERBB3_HUMAN	Decreases Expression	[32]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Decreases Expression	[40]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Increases Phosphorylation	[51]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Increases Phosphorylation	[51]
Retinoblastoma-like protein 1 (RBL1)	OTDEBFYC	RBL1_HUMAN	Decreases Expression	[52]
Protein PML (PML)	OT6SM2GD	PML_HUMAN	Decreases Degradation	[53]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Increases Phosphorylation	[12]
Pro-adrenomedullin (ADM)	OT7T0TA4	ADML_HUMAN	Increases Expression	[54]
Receptor-type tyrosine-protein kinase FLT3 (FLT3)	OTMSRYMK	FLT3_HUMAN	Decreases Expression	[55]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Decreases Expression	[56]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[57]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Increases Expression	[58]
E3 ubiquitin-protein ligase RNF4 (RNF4)	OTCMXQRE	RNF4_HUMAN	Decreases Expression	[59]
Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)	OTTM6KRB	ADA17_HUMAN	Decreases Stability	[60]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Decreases Activity	[61]
Urokinase plasminogen activator surface receptor (PLAUR)	OTIRKKEQ	UPAR_HUMAN	Increases Expression	[62]
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Affects Localization	[63]
Recombining binding protein suppressor of hairless (RBPJ)	OTD7CUG0	SUH_HUMAN	Decreases Expression	[64]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Decreases Expression	[43]
Bcl-2-like protein 1 (BCL2L1)	OTRC5K9O	B2CL1_HUMAN	Increases Expression	[65]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Decreases Expression	[66]
TAR DNA-binding protein 43 (TARDBP)	OTVOSFWW	TADBP_HUMAN	Decreases Expression	[67]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Decreases Expression	[68]
Caspase-8 (CASP8)	OTA8TVI8	CASP8_HUMAN	Increases Activity	[69]
Nuclear factor erythroid 2-related factor 2 (NFE2L2)	OT0HENJ5	NF2L2_HUMAN	Decreases Expression	[70]
Hypoxia-inducible factor 1-alpha (HIF1A)	OTADSC03	HIF1A_HUMAN	Increases Degradation	[18]
Protein NDRG1 (NDRG1)	OTVO66BO	NDRG1_HUMAN	Decreases Expression	[71]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Decreases Activity	[72]
Sodium/iodide cotransporter (SLC5A5)	OTU7E9G7	SC5A5_HUMAN	Increases Expression	[73]
Transcription termination factor 3, mitochondrial (MTERF3)	OTVE8W7X	MTEF3_HUMAN	Decreases Expression	[74]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1)	OTAYZMOY	SIR1_HUMAN	Decreases Expression	[75]
Proheparin-binding EGF-like growth factor (HBEGF)	OTLU00JS	HBEGF_HUMAN	Increases Expression	[32]
Endothelial PAS domain-containing protein 1 (EPAS1)	OTRE3O8U	EPAS1_HUMAN	Decreases Expression	[76]
Repressor of RNA polymerase III transcription MAF1 homolog (MAF1)	OTKB0N8Q	MAF1_HUMAN	Increases Degradation	[77]
Tumor necrosis factor (TNF)	OT4IE164	TNFA_HUMAN	Increases Response To Substance	[78]
MAP kinase-activated protein kinase 3 (MAPKAPK3)	OT7IWJNI	MAPK3_HUMAN	Affects Response To Substance	[19]
D-ribitol-5-phosphate cytidylyltransferase (CRPPA)	OTC85K8Q	ISPD_HUMAN	Affects Response To Substance	[19]
Rab9 effector protein with kelch motifs (RABEPK)	OTCZSREH	RABEK_HUMAN	Affects Response To Substance	[19]
Kremen protein 1 (KREMEN1)	OTGJFSAC	KREM1_HUMAN	Affects Response To Substance	[19]
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Increases Response To Substance	[79]
Unconventional myosin-Id (MYO1D)	OTP2RGPN	MYO1D_HUMAN	Affects Response To Substance	[19]
Cation channel sperm-associated protein 4 (CATSPER4)	OTXJ4E8J	CTSR4_HUMAN	Affects Response To Substance	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 120 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Hodgkin lymphoma	DC5VAJZ	U-HO1	Investigative	[1]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7945).
3	UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5433).
5	Chemerin promotes the pathogenesis of preeclampsia by activating CMKLR1/p-Akt/CEBP axis and inducing M1 macrophage polarization. Cell Biol Toxicol. 2022 Aug;38(4):611-628. doi: 10.1007/s10565-021-09636-7. Epub 2021 Aug 16.
6	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95.
7	Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Sci Rep. 2016 Nov 29;6:37997. doi: 10.1038/srep37997.
8	Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
9	PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.
10	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget. 2012 Aug;3(8):811-23. doi: 10.18632/oncotarget.579.
11	-Mangostin alleviates liver fibrosis through Sirtuin 3-superoxide-high mobility group box 1 signaling axis. Toxicol Appl Pharmacol. 2019 Jan 15;363:142-153. doi: 10.1016/j.taap.2018.11.011. Epub 2018 Nov 29.
12	Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
13	Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
14	Estrogen regulation of the glucuronidation enzyme UGT2B15 in estrogen receptor-positive breast cancer cells. Endocrinology. 2006 Aug;147(8):3843-50.
15	Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells. Toxicology. 2019 Apr 1;417:54-63.
16	Suppressed translation and ULK1 degradation as potential mechanisms of autophagy limitation under prolonged starvation. Autophagy. 2016 Nov;12(11):2085-2097. doi: 10.1080/15548627.2016.1226733. Epub 2016 Sep 14.
17	Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. Chem Biol Interact. 2022 Jun 1;360:109938. doi: 10.1016/j.cbi.2022.109938. Epub 2022 Apr 12.
18	Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J Biol Chem. 2001 Dec 21;276(51):48066-76. doi: 10.1074/jbc.M106282200. Epub 2001 Oct 18.
19	Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
20	Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87.
21	A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol. 1995 Oct;48(4):682-9.
22	Superinduction of CYP1A1 in MCF10A cultures by cycloheximide, anisomycin, and puromycin: a process independent of effects on protein translation and unrelated to suppression of aryl hydrocarbon receptor proteolysis by the proteasome. Mol Pharmacol. 2004 Oct;66(4):936-47.
23	Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
24	Comparative analysis of AhR-mediated TCDD-elicited gene expression in human liver adult stem cells. Toxicol Sci. 2009 Nov;112(1):229-44.
25	The effect of interferon-alpha on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol. 2011 Jun 1;253(2):130-6.
26	Metabolism of bilirubin by human cytochrome P450 2A6. Toxicol Appl Pharmacol. 2012 May 15;261(1):50-8.
27	Aryl hydrocarbon receptor-dependent up-regulation of the heterodimeric amino acid transporter LAT1 (SLC7A5)/CD98hc (SLC3A2) by diesel exhaust particle extract in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2016 Jan 1;290:74-85.
28	Instability of the human cytochrome p450 reductase A287P variant is the major contributor to its antley-bixler syndrome-like phenotype. J Biol Chem. 2016 Sep 23;291(39):20487-502.
29	Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells. J Gastroenterol. 2009;44(5):460-9. doi: 10.1007/s00535-009-0030-1. Epub 2009 Apr 1.
30	Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
31	Tetrachlorobenzoquinone induces Nrf2 activation via rapid Bach1 nuclear export/ubiquitination and JNK-P62 signaling. Toxicology. 2016 Jul 1;363-364:48-57. doi: 10.1016/j.tox.2016.07.002. Epub 2016 Jul 5.
32	The DNA damaging agent VP16 induces the expression of a subset of ligands from the EGF system in bladder cancer cells, whereas none of the four EGF receptors are induced. Mol Cell Biochem. 2004 May;260(1-2):129-35. doi: 10.1023/b:mcbi.0000026063.96267.98.
33	Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis. J Biol Chem. 2003 Jun 6;278(23):21295-306. doi: 10.1074/jbc.M212837200. Epub 2003 Mar 27.
34	Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J Biol Chem. 2018 Jan 5;293(1):163-176. doi: 10.1074/jbc.M117.814111. Epub 2017 Nov 6.
35	Transcriptional regulation of UCP4 by NF-kappaB and its role in mediating protection against MPP+ toxicity. Free Radic Biol Med. 2010 Jul 15;49(2):192-204. doi: 10.1016/j.freeradbiomed.2010.04.002. Epub 2010 Apr 9.
36	Induction of c-fos proto-oncogene in mesangial cells by cadmium. J Biol Chem. 1998 Jan 2;273(1):73-9. doi: 10.1074/jbc.273.1.73.
37	Quercetin up-regulates LDL receptor expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1688-94. doi: 10.1002/ptr.4646. Epub 2012 Mar 3.
38	Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
39	Xenoestrogens alter estrogen receptor (ER) intracellular levels. PLoS One. 2014 Feb 20;9(2):e88961. doi: 10.1371/journal.pone.0088961. eCollection 2014.
40	IkappaBalpha (inhibitory kappaBalpha) identified as labile repressor of MnSOD (manganese superoxide dismutase) expression. Biochem J. 2004 Dec 15;384(Pt 3):543-9. doi: 10.1042/BJ20040714.
41	Characterization of cytochrome P4502E1 turnover in transfected HepG2 cells expressing human CYP2E1. Arch Biochem Biophys. 1997 May 1;341(1):25-33. doi: 10.1006/abbi.1997.9907.
42	The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNF-induced liver injury. J Hepatol. 2011 Apr;54(4):674-84. doi: 10.1016/j.jhep.2010.07.028. Epub 2010 Sep 27.
43	Effect of cytokines on ICAM-1 and ZO-1 expression on human airway epithelial cells. Cell Biol Int. 2005 Sep;29(9):768-77. doi: 10.1016/j.cellbi.2005.05.002.
44	Linc-ROR drive adriamycin resistance by targeting AP-2/Wnt/-catenin axis in hepatocellular carcinoma. Cell Biol Toxicol. 2023 Aug;39(4):1735-1752. doi: 10.1007/s10565-022-09777-3. Epub 2022 Dec 28.
45	Dual regulation of 2-adrenoceptor messenger RNA expression in human lung fibroblasts by 2-cAMP signaling; delayed upregulated inhibitors oppose a rapid in onset, direct stimulation of gene expression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Jul;387(7):649-57. doi: 10.1007/s00210-014-0971-7. Epub 2014 Apr 8.
46	RNF168 suppresses the cancer stem cell-like traits of nonsmall cell lung cancer cells by mediating RhoC ubiquitination. Environ Toxicol. 2022 Mar;37(3):603-611. doi: 10.1002/tox.23428. Epub 2021 Dec 7.
47	Inhibition of breast cancer cell growth and induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM. Cancer Lett. 2006 May 18;236(2):198-212. doi: 10.1016/j.canlet.2005.05.036. Epub 2005 Jul 26.
48	Deoxynivalenol affects in vitro intestinal epithelial cell barrier integrity through inhibition of protein synthesis. Toxicol Appl Pharmacol. 2010 Jun 15;245(3):291-8. doi: 10.1016/j.taap.2010.03.012. Epub 2010 Apr 1.
49	Redox-sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenic. J Cell Biochem. 2009 Jun 1;107(3):537-47. doi: 10.1002/jcb.22155.
50	ERR contributes to HDAC6-induced chemoresistance of osteosarcoma cells. Cell Biol Toxicol. 2023 Jun;39(3):813-825. doi: 10.1007/s10565-021-09651-8. Epub 2021 Sep 15.
51	Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways. Eur J Pharmacol. 2004 Apr 12;489(3):139-49. doi: 10.1016/j.ejphar.2004.03.004.
52	Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May;138(5):1920-30. doi: 10.1053/j.gastro.2010.01.007. Epub 2010 Jan 25.
53	Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):191-201. doi: 10.1016/j.taap.2015.05.018. Epub 2015 Jun 3.
54	Induction of adrenomedullin during hypoxia in cultured human glioblastoma cells. J Neurochem. 2000 Nov;75(5):1826-33. doi: 10.1046/j.1471-4159.2000.0751826.x.
55	Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells. J Cancer. 2020 Mar 13;11(12):3476-3482. doi: 10.7150/jca.29751. eCollection 2020.
56	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
57	G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother. 2005 Aug;54(8):729-40. doi: 10.1007/s00262-004-0645-2. Epub 2005 Feb 1.
58	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exposure of normal human dermal fibroblasts results in AhR-dependent and -independent changes in gene expression. Toxicol Appl Pharmacol. 2007 Apr 1;220(1):9-17. doi: 10.1016/j.taap.2006.12.002. Epub 2006 Dec 15.
59	Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010 Dec;21(23):4227-39. doi: 10.1091/mbc.E10-05-0449. Epub 2010 Oct 13.
60	Antiviral Potential of Small Molecules Cordycepin, Thymoquinone, and N6, N6-Dimethyladenosine Targeting SARS-CoV-2 Entry Protein ADAM17. Molecules. 2022 Dec 19;27(24):9044. doi: 10.3390/molecules27249044.
61	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
62	Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol Immunother. 2002 Jul;51(5):248-54. doi: 10.1007/s00262-002-0275-5. Epub 2002 Apr 9.
63	Inactivation of IkappaB contributes to transcriptional activation of spermidine/spermine N(1)-acetyltransferase. Mol Carcinog. 2006 Sep;45(9):685-93. doi: 10.1002/mc.20239.
64	Presenilin-2 regulates the degradation of RBP-Jk protein through p38 mitogen-activated protein kinase. J Cell Sci. 2012 Mar 1;125(Pt 5):1296-308. doi: 10.1242/jcs.095984. Epub 2012 Feb 2.
65	Dexamethasone suppresses apoptosis in a human gastric cancer cell line through modulation of bcl-x gene expression. FEBS Lett. 1997 Sep 22;415(1):11-5. doi: 10.1016/s0014-5793(97)01083-1.
66	Interleukin-15 delays human neutrophil apoptosis by intracellular events and not via extracellular factors: role of Mcl-1 and decreased activity of caspase-3 and caspase-8. J Leukoc Biol. 2004 May;75(5):893-900. doi: 10.1189/jlb.1103585. Epub 2004 Feb 24.
67	Disease-associated mutations of TDP-43 promote turnover of the protein through the proteasomal pathway. Mol Neurobiol. 2014 Dec;50(3):1049-58. doi: 10.1007/s12035-014-8644-6. Epub 2014 Jan 30.
68	Enhanced p62-NRF2 Feedback Loop due to Impaired Autophagic Flux Contributes to Arsenic-Induced Malignant Transformation of Human Keratinocytes. Oxid Med Cell Longev. 2019 Oct 30;2019:1038932. doi: 10.1155/2019/1038932. eCollection 2019.
69	Resistance to Fas-mediated apoptosis is restored by cycloheximide through the downregulation of cellular FLIPL in NK/T-cell lymphoma. Lab Invest. 2005 Jul;85(7):874-84. doi: 10.1038/labinvest.3700291.
70	Nrf2 Expression and Apoptosis in Quercetin-treated Malignant Mesothelioma Cells. Mol Cells. 2015 May;38(5):416-25. doi: 10.14348/molcells.2015.2268. Epub 2015 Apr 21.
71	NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy. Cell Death Dis. 2017 Sep 14;8(9):e3048. doi: 10.1038/cddis.2017.438.
72	The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem. 2001 Aug 10;276(32):30183-7. doi: 10.1074/jbc.C100325200. Epub 2001 Jun 25.
73	Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor. J Clin Endocrinol Metab. 2007 Mar;92(3):1080-7. doi: 10.1210/jc.2006-2106. Epub 2006 Dec 12.
74	MTERF3 contributes to MPP+-induced mitochondrial dysfunction in SH-SY5Y cells. Acta Biochim Biophys Sin (Shanghai). 2022 Aug 25;54(8):1113-1121. doi: 10.3724/abbs.2022098.
75	JNK activation-mediated nuclear SIRT1 protein suppression contributes to silica nanoparticle-induced pulmonary damage via p53 acetylation and cytoplasmic localisation. Toxicology. 2019 Jul 1;423:42-53. doi: 10.1016/j.tox.2019.05.003. Epub 2019 May 11.
76	A MALAT1/HIF-2 feedback loop contributes to arsenite carcinogenesis. Oncotarget. 2016 Feb 2;7(5):5769-87. doi: 10.18632/oncotarget.6806.
77	The RNA polymerase III repressor MAF1 is regulated by ubiquitin-dependent proteasome degradation and modulates cancer drug resistance and apoptosis. J Biol Chem. 2019 Dec 13;294(50):19255-19268. doi: 10.1074/jbc.RA119.008849. Epub 2019 Oct 23.
78	Position of STAT-1 alpha in cycloheximide-dependent apoptosis triggered by TNF-alpha in human colorectal COLO 205 cancer cell line; role of polyphenolic compounds. J Physiol Pharmacol. 2005 Jun;56 Suppl 3:119-41.
79	Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol. 2011 Dec;80(6):1000-12. doi: 10.1124/mol.111.074708. Epub 2011 Aug 29.